Actively Recruiting
Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening
Led by The Filatov Institute of Eye Diseases and Tissue Therapy · Updated on 2025-03-17
200
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
Sponsors
T
The Filatov Institute of Eye Diseases and Tissue Therapy
Lead Sponsor
C
CheckEye LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
To examine the potential for the detection of diabetic retinopathy (DR) using the artificial intelligence (AI)-based software platform Retina-AI.
CONDITIONS
Official Title
Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented diagnosis of diabetes mellitus
- Willingness and ability to understand the study and sign informed consent
- Age 18 years or older
- Diagnosis of type 1 diabetes for at least 5 years or type 2 diabetes
You will not qualify if you...
- Under 18 years of age
- Failure to give informed consent
- Presence of retinal diseases such as age-related macular degeneration, retinal vessel occlusion, coloboma, retinitis pigmentosa, or angioid streaks
- Previous treatment (surgery, laser, etc.) for retinal diseases like age-related macular degeneration or retinal vascular occlusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Filatov Institute of Eye Diseases and Tissue Therapy
Odesa, Ukraine, 65061
Actively Recruiting
Research Team
A
Andrii MD Korol, PhD
CONTACT
O
Olha MD Pohosian
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here